Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4 (Q57267967)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 November 2000

Language	Label	Description	Also known as
English	Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4	scientific article published on 01 November 2000

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4 (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

0 references

multiple sclerosis

0 references

0 references

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

A Bergami

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

R Lang

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

E Brambilla

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

D Franciotta

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

V Martinelli

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

G Comi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

P Panina

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

G Martino

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 November 2000

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Journal of Neuroimmunology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

111

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

86-92

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Functional diversity of helper T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Mouse CD1-specific NK1 T cells: development, specificity, and function

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine gene expression in cells derived from CSF of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Th-cell modulation in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunopathogenesis of multiple sclerosis: the role of T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The expanding universe of T-cell subsets: Th1, Th2 and more.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunomodulatory effects of interferon-beta-1b in vivo: induction of the expression of transforming growth factor-beta1 and its receptor type II

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Exacerbations of multiple sclerosis in patients treated with gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes of serum sICAM-1 and MMP-9 induced by rIFN -1b treatment in relapsing-remitting MS

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900377-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0165-5728(00)00377-5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11063825%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57267967&oldid=1754707641"